Monday, January 25, 2016
Predicting Peanut Allergy Immunotherapy Outcomes
A new NIAID-funded study suggests the potential to predict outcomes of oral immunotherapy for peanut allergy, an investigational therapy that aims to induce long-term tolerance to peanut. Investigators at Stanford University found that immunotherapy causes early, distinct changes in immune T-cell populations. Although more work is needed, detailed T-cell analysis potentially may be useful for helping scientists understand which peanut-allergic people are most likely to benefit from the therapy and which immune mechanisms are involved in the response.
For Immediate Release: Monday, Jan. 25, 2016
MEDIA AVAILABILITY
NIH-Funded Study Suggests Potential to Predict Peanut Allergy Immunotherapy Outcomes
Successful Immunotherapy Induces Changes in Immune Cell Subtypes
Oral immunotherapy for peanut allergy induces early, distinct changes in immune T-cell populations that potentially may help researchers determine which people will respond well to the therapy and which immune mechanisms are involved in the response, a new study suggests. The work was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by scientists at Stanford University.
The researchers examined blood samples taken from peanut-allergic volunteers enrolled in an oral immunotherapy study. Participants consumed small, gradually increasing daily doses of peanut protein for 24 months with the ultimate goal of inducing long-term tolerance to peanut. Using advanced laboratory techniques, the scientists tracked changes in peanut-specific T cells in five participants during the first 18 months of peanut immunotherapy. They compared these results with those from blood samples taken before the start of immunotherapy and from healthy, non-allergic volunteers. Immunotherapy caused an increase in peanut-specific T cells, accompanied by a change in the distribution of T-cell subtypes over time. With treatment, T-cell subtypes normally associated with allergic responses diminished, while a novel T-cell population that likely would not mount an allergic response expanded.
These preliminary findings show the power of this approach to analyze and monitor allergen-specific immune cell changes during immunotherapy. Future studies with more patients will help determine whether this type of detailed T-cell analysis is useful for predicting which peanut-allergic individuals are most likely to benefit from this investigational therapy.
ARTICLE:
JF Ryan et al. Successful immunotherapy induces novel allergen-specific CD4+ T cell subsets. Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.1520180113 (2016).
JF Ryan et al. Successful immunotherapy induces novel allergen-specific CD4+ T cell subsets. Proceedings of the National Academy of Sciences DOI: 10.1073/pnas.1520180113 (2016).
WHO:
Wendy Davidson, Ph.D., a program officer in the Allergy, Asthma and Airway Biology Branch in NIAID’s Division of Allergy, Immunology and Transplantation, is available to discuss the findings.
Wendy Davidson, Ph.D., a program officer in the Allergy, Asthma and Airway Biology Branch in NIAID’s Division of Allergy, Immunology and Transplantation, is available to discuss the findings.
CONTACT:
To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, niaidnews@niaid.nih.gov.
To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, niaidnews@niaid.nih.gov.
No hay comentarios:
Publicar un comentario